Involvement of transforming growth factor beta-1 (TGFβ1) cytokine and FOXP3 transcription factor genetic polymorphisms in hematological malignancies

Abstract

Hematological malignancies (HM) are a group of neoplastic diseases that (OR = 4.07;). In the combined analysis, a positive association was also observed for TGFB1 TT and FOXP3 GG genotypes (OR = 4.00;

Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia

“…Regarding TGF-β1 rs1800470, our findings were similar to those of a study performed in Brazil which demonstrated that the TGF-β1 rs1800470 TT homozygous genotype was associated with an increased risk of developing hematological malignancies (OR = 4.07; 95% CI: 1.94-8.52; P = .0002), with a 4-fold increase in the risk of developing hematological cancers. 18 Pehlivan et al found no significant differences between Turkish patients with Philadelphia positive CML and their controls. 13 Contrary to our observations, no difference was observed in a Turkish population for the TGF-β1 rs1800470 variant genotype.…”

“…Therefore, it is necessary to evaluate more than one SNP in the same study to take into account the polygenic model of inherited cancer susceptibility. 18 To the best of the authors' knowledge, there are no published studies describing the possible association between and cytogenetic high-risk were independent significant predictors for death in AML (P = .04, corrected HR = 1.20; P = .022, corrected HR = 1.24; P = .021, corrected HR = 1.34, respectively). Conclusions: Age above 65 years, PLT count, TNF-α rs1800750 variant genotype, blast percentage, LDH level, and cytogenetic high-risk may be used as independent risk factors to assess AML mortality.…”

“…Carcinogenesis is affected by the action of several genes, in which an isolated SNP plays only a small role. Therefore, it is necessary to evaluate more than one SNP in the same study to take into account the polygenic model of inherited cancer susceptibility …”